Article in ACS sensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 1 country.
Michael RappleyeDepartment of Bioengineering, University of Washington, 850 Republican Street, Seattle, Washington 98105, United States.ORCID 0000-0002-2885-3406
Sarah J WaitInstitute of Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, Washington 98109, United States.ORCID 0000-0001-5660-2391
Justin Daho LeeInstitute of Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, Washington 98109, United States.ORCID 0000-0002-0284-2389
Jamison C SiebartThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Dr NW, Atlanta, Georgia 30332, United States.ORCID 0000-0002-0424-7487
Lily TorpDepartment of Bioengineering, University of Washington, 850 Republican Street, Seattle, Washington 98105, United States.
Netta SmithDepartment of Bioengineering, University of Washington, 850 Republican Street, Seattle, Washington 98105, United States.
Jeanot MusterDepartment of Bioengineering, University of Washington, 850 Republican Street, Seattle, Washington 98105, United States.ORCID 0000-0002-1972-6851
Kenneth A MatreyekDepartment of Pathology, Case Western Reserve University School of Medicine, 2103 Cornell Road, Wolstein Research Building, Cleveland, Ohio 44106, United States.ORCID 0000-0001-9149-551X
Douglas M FowlerDepartment of Genome Sciences, Foege Building S-250, 3720 15th Ave NE, Seattle, Washington 98195-5065, United States.ORCID 0000-0001-7614-1713
Andre BerndtDepartment of Bioengineering, University of Washington, 850 Republican Street, Seattle, Washington 98105, United States.ORCID 0000-0003-4758-5598
University of Washington · USCornell University · USGeorgia Institute of Technology · US
Funding
Technology to understand genetic variant effects in contextRM1HG010461 · NHGRI · UNIVERSITY OF WASHINGTON · PI Douglas M Fowler, Bruce Colston Trapnell · 2019 to 2026
$18.9M
University of Washington Center of Excellence in Opioid Addiction ResearchP30DA048736 · NIDA · UNIVERSITY OF WASHINGTON · PI Charles Chavkin · 2019 to 2026
$13.0M
Next Generation Opto-GPCRs for Neuromodulatory ControlU01NS128537 · NINDS · UNIVERSITY OF WASHINGTON · PI Andre Berndt, Michael R. Bruchas · 2023 to 2026
$4.4M
High-throughput engineering of ligand-selective fluorescent biosensors for detecting endogenous and exogenous opioidsRF1MH130391 · NIMH · UNIVERSITY OF WASHINGTON · PI BERNDT, ANDRE, BRUCHAS, MICHAEL R. · 2023 to 2023
$2.5M
Large-Scale Methods for Assessing the Consequences of Mutations in ProteinsR01GM109110 · NIGMS · UNIVERSITY OF WASHINGTON · PI FOWLER, DOUGLAS M · 2014 to 2021
$2.4M
Recombinant DNA technologies for multiplex genetic assays in human cellsR35GM142886 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI MATREYEK, KENNETH A · 2021 to 2025
$2.0M
Structure-guided and high-throughput engineering of genetically encoded sensors for reactive oxygen speciesR01GM139850 · NIGMS · UNIVERSITY OF WASHINGTON · PI BERNDT, ANDRE · 2021 to 2024
$1.6M
Physiological and Molecular Mechanisms of Mu Opioid Receptors in Motivation and AffectR00DA049862 · NIDA · WASHINGTON UNIVERSITY · PI CASTRO, DANIEL CHARLES · 2022 to 2024
$747k
In vivo real-time monitoring of reactive oxygen species and opioid signaling in a model for opioid receptor activity.R21DA051193 · NIDA · UNIVERSITY OF WASHINGTON · PI BERNDT, ANDRE · 2021 to 2022
$461k
Physiological and Molecular Mechanisms of Mu Opioid Receptors in Motivation and AffectK99DA049862 · NIDA · UNIVERSITY OF WASHINGTON · PI CASTRO, DANIEL CHARLES · 2020 to 2021
$284k
Deciphering biased agonistic activation of mu-opioid receptor by novel optogenetic hydrogen peroxide sensorF31DA056121 · NIDA · UNIVERSITY OF WASHINGTON · PI LEE, JUSTIN · 2022 to 2024
Genetically encoded fluorescent indicators (GEFIs) are protein-based optogenetic tools that change their fluorescence intensity when binding specific ligands in cells and tissues. GEFI encoding DNA can be expressed in cell subtypes while monitoring cellular physiological responses. However, engineering GEFIs with physiological sensitivity and pharmacological specificity often requires iterative optimization through trial-and-error mutagenesis while assessing their biophysical function
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Optogenetic Microwell Array Screening System: A High-Throughput Engineering Platform for Genetically Encoded Fluorescent Indicators. · full record | OpenQuestion